ACELYRIN, INC. Common Stock (SLRN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ACELYRIN, INC. Common Stock (SLRN) has a cash flow conversion efficiency ratio of -0.096x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-38.95 Million) by net assets ($407.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ACELYRIN, INC. Common Stock market capitalisation for the company's overall valuation and market capitalisation.
ACELYRIN, INC. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how ACELYRIN, INC. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
ACELYRIN, INC. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ACELYRIN, INC. Common Stock ranked by their cash flow conversion efficiency. See SLRN operating cash flow to total debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Harvatek Corp
TW:6168
|
-0.006x |
|
Shenzhen Auto Electric Power Plant Co Ltd
SHE:002227
|
0.015x |
|
Mildef Crete
TWO:3213
|
0.069x |
|
Squirrel Media SA
MC:SQRL
|
0.076x |
|
Reach Subsea
OL:REACH
|
0.131x |
|
Guangdong Modern High Tech Fiber Co
SHE:300876
|
0.037x |
|
Hawthorn Bancshares Inc
NASDAQ:HWBK
|
0.087x |
|
NervGen Pharma Corp.
NASDAQ:NGEN
|
-0.336x |
Annual Cash Flow Conversion Efficiency for ACELYRIN, INC. Common Stock (2021–2024)
The table below shows the annual cash flow conversion efficiency of ACELYRIN, INC. Common Stock from 2021 to 2024. View SLRN share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $458.29 Million | $-303.92 Million | -0.663x | -156.48% |
| 2023-12-31 | $656.34 Million | $-169.71 Million | -0.259x | -146.82% |
| 2022-12-31 | $-111.39 Million | $-61.52 Million | 0.552x | +366.50% |
| 2021-12-31 | $-42.06 Million | $-4.98 Million | 0.118x | -- |
About ACELYRIN, INC. Common Stock
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorp… Read more